Targeting ACSM3 resulted in reduced tumor growth, revealing a link between AR and lipid metabolism, and future development of drugs targeting ACSM1 and ACSM3 is expected to explore new therapies in combination with traditional ADT therapy 116. The gene discussed is ACSM1; the disease is neoplasm.